Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.10.3.1 (
tyrosinase
)
9,065
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Melanogenesis is a principal parameter of differentiation in melanocytes and melanoma cells. Our recent study has demonstrated that
phospholipase D1
(
PLD1
) regulates the melanogenic signaling through modulating the expression of
tyrosinase
, the rate-limiting step enzyme in the melanin biosynthesis. The current study was designed to gain more insight into the involvement of
PLD1
in the regulation of melanogenesis. To investigate the role of
PLD1
, we examined the effect of knockdown of endogenous
PLD1
by small interference RNA (siRNA) on melanogenesis in B16 melanoma cells. It was shown that the melanin synthesis was induced in
PLD1
-knockdowned cells, and also that the level of melanin synthesis was well correlated with increases in expression level of
tyrosinase
and its related proteins (Tyrp1 and Dct). Furthermore, the reduction of expression levels of
PLD1
by siRNA transfection was accompanied by diminution of ribosomal S6 kinase 1 (S6K1) phosphorylation. The activity of mammalian target of rapamycin (mTOR) is essential for phosphorylation of S6K1 and the treatment malanoma cells with rapamycin, a potent inhibitor of mTOR effectively induced melanogenesis. The results obtained here provide possible evidence that
PLD1
exerts a negative regulatory role in the melanogenic process through mTOR/S6K1 signaling.
...
PMID:Negative regulation of melanogenesis by phospholipase D1 through mTOR/p70 S6 kinase 1 signaling in mouse B16 melanoma cells. 1589 62
